Home › Companies › Arcutis Biotherapeutics, Inc. › 2025-2026

Arcutis Biotherapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Arcutis Biotherapeutics, Inc.’s Form 8-K, filed 2026-06-09 (Item 5.07 on EDGAR). Page generated 02 October 2026.

5Reported items
307Asset managers
1,547Fund votes
2026-06-05Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Arcutis Biotherapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Arcutis Biotherapeutics, Inc.

These tallies are Arcutis Biotherapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-09 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Arcutis Biotherapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-05
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Patrick J. Heron	62,830,439	--	--	30,446,098	14,868,017	Majority: yes
Elect Director: Neha Krishnamohan	74,956,903	--	--	18,319,634	14,868,017	Majority: yes
Elect Director: Todd Franklin Watanabe	75,771,853	--	--	17,504,684	14,868,017	Majority: yes
Proposal 3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers:	88,728,269	3,723,408	824,860	--	14,868,017	Majority: yes

Source: Arcutis Biotherapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-09 — read the filing on EDGAR.

How asset managers voted at the Arcutis Biotherapeutics, Inc. 2025-2026 meeting

Each item below shows how the 307 asset managers that disclosed a Arcutis Biotherapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Arcutis Biotherapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 88,728,269AGAINST: 3,723,408

Arcutis Biotherapeutics, Inc.’s own tally for this item (“Proposal 3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers:”): 88,728,269 for, 3,723,408 against, per its Form 8-K filed 2026-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 125,042,000 outstanding shares: 71% for, 3% against (74% of the company cast a for/against vote).

The 303 asset managers below cast 96% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 96%

FOR: 96.2%AGAINST: 3.8%ABSTAIN: 0.0%NOT VOTED: 0.0%

Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.” at Arcutis Biotherapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
MONTANOVA CAPITAL, LLC	11,785,519	0	0	For
Polar Capital Holdings Plc	10,719,320	0	0	For
Frazier Life Sciences Management, L.P.	9,874,511	0	0	For
Vanguard	7,833,222	6	3	For
BlackRock	6,947,117	656	0	For
State Street	6,103,886	3,852	0	For
JENNISON ASSOCIATES LLC	4,294,741	0	0	For
Rubric Capital Management LP	4,151,354	0	0	For
Fidelity	3,282,696	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	3,047,912	0	0	For
Prudential/PGIM	2,379,772	2,300	0	For
American Century	0	2,363,259	0	Against
FRANKLIN ADVISERS INC	2,270,457	0	0	For
Charles Schwab	2,026,091	0	0	For
Federated Hermes	1,749,142	0	0	For
OBERWEIS ASSET MANAGEMENT INC/	1,365,941	0	0	For
Ensign Peak Advisors, Inc	1,244,387	0	0	For
OBERWEIS FUNDS	1,211,800	0	0	For
DRIEHAUS CAPITAL MANAGEMENT LLC	1,179,449	0	0	For
Janus Henderson	1,135,958	0	0	For
Candriam S.C.A.	0	1,086,651	0	Against
DE Shaw	986,579	0	0	For
BAMCO INC /NY/	930,000	0	0	For
Northern Trust	915,293	0	0	For
Nuveen	900,216	0	0	For

Showing the 25 largest of 303 asset managers. See all 303 in the interactive database.

2. Election of Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: Neha Krishnamohan

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD 20%

FOR: 74,956,903WITHHELD: 18,319,634

Arcutis Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Neha Krishnamohan”): 74,956,903 for, 18,319,634 withheld, per its Form 8-K filed 2026-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 125,042,000 outstanding shares: 60% for, 15% withheld (75% of the company cast a for/withheld vote).

The 87 asset managers below cast 100% of the shares they voted on this item FOR (26,182,809 for, 0 against).

FOR 85%ABSTAIN 15%

FOR: 26,182,809 (84.7%)ABSTAIN: 4,712,951 (15.3%)

Largest asset managers voting on “Election of Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their su” at Arcutis Biotherapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	6,849,997	55,484	For
State Street	3,804,213	4,442	For
BlackRock	3,277,010	0	For
Fidelity	2,954,046	53,100	For
Prudential/PGIM	2,217,792	3,298	For
OBERWEIS FUNDS	0	1,211,800	Abstain
American Century	0	1,120,551	Abstain
Charles Schwab	1,012,955	0	For
TIAA	870,242	0	For
FRANKLIN STRATEGIC SERIES	850,058	0	For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)	710,000	0	For
Federated Hermes	689,843	0	For
Franklin Custodian Funds	400,000	0	For
DRIEHAUS MUTUAL FUNDS	0	396,980	Abstain
First Trust	0	351,058	Abstain
Bridge Builder Trust	334,408	0	For
T. Rowe Price	281,489	0	For
Equitable	156,363	74,380	For
AMG FUNDS	230,038	0	For
Jackson National	147,000	56,192	For
AIG/SunAmerica	0	179,784	Abstain
BUFFALO FUNDS	173,306	0	For
Principal Exchange-Traded Funds	0	163,367	Abstain
Lincoln Financial	74,800	68,824	For
Allspring	0	132,842	Abstain

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

3. Election of Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: Patrick J. Heron

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

67% Majority: yes · of votes cast

FOR 67%WITHHELD 33%

FOR: 62,830,439WITHHELD: 30,446,098

Arcutis Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Patrick J. Heron”): 62,830,439 for, 30,446,098 withheld, per its Form 8-K filed 2026-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 125,042,000 outstanding shares: 50.2% for, 24% withheld (75% of the company cast a for/withheld vote).

The 87 asset managers below cast 100% of the shares they voted on this item FOR (22,200,421 for, 0 against).

FOR 72%ABSTAIN 28%

FOR: 22,200,421 (71.9%)ABSTAIN: 8,695,339 (28.1%)

Largest asset managers voting on “Election of Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their su” at Arcutis Biotherapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	6,849,964	55,517	For
State Street	7,680	3,800,975	Abstain
BlackRock	3,277,010	0	For
Fidelity	2,954,046	53,100	For
Prudential/PGIM	2,217,792	3,298	For
OBERWEIS FUNDS	0	1,211,800	Abstain
American Century	0	1,120,551	Abstain
Charles Schwab	1,012,955	0	For
TIAA	870,242	0	For
FRANKLIN STRATEGIC SERIES	850,058	0	For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)	710,000	0	For
Federated Hermes	689,843	0	For
Franklin Custodian Funds	400,000	0	For
DRIEHAUS MUTUAL FUNDS	0	396,980	Abstain
First Trust	0	351,058	Abstain
Bridge Builder Trust	334,408	0	For
T. Rowe Price	281,489	0	For
Equitable	156,363	74,380	For
AMG FUNDS	230,038	0	For
Jackson National	147,000	56,192	For
AIG/SunAmerica	0	179,784	Abstain
BUFFALO FUNDS	173,306	0	For
Principal Exchange-Traded Funds	0	163,367	Abstain
Lincoln Financial	0	143,624	Abstain
Allspring	0	132,842	Abstain

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

4. Election of Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: Todd Franklin Watanabe

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD 19%

FOR: 75,771,853WITHHELD: 17,504,684

Arcutis Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Todd Franklin Watanabe”): 75,771,853 for, 17,504,684 withheld, per its Form 8-K filed 2026-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 125,042,000 outstanding shares: 61% for, 14% withheld (75% of the company cast a for/withheld vote).

The 87 asset managers below cast 100% of the shares they voted on this item FOR (26,332,327 for, 0 against).

FOR 85%ABSTAIN 15%

FOR: 26,332,327 (85.2%)ABSTAIN: 4,563,433 (14.8%)

Largest asset managers voting on “Election of Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their su” at Arcutis Biotherapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	6,849,999	55,482	For
State Street	3,804,213	4,442	For
BlackRock	3,277,010	0	For
Fidelity	2,954,046	53,100	For
Prudential/PGIM	2,217,792	3,298	For
OBERWEIS FUNDS	0	1,211,800	Abstain
American Century	0	1,120,551	Abstain
Charles Schwab	1,012,955	0	For
TIAA	870,242	0	For
FRANKLIN STRATEGIC SERIES	850,058	0	For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)	710,000	0	For
Federated Hermes	689,843	0	For
Franklin Custodian Funds	400,000	0	For
DRIEHAUS MUTUAL FUNDS	0	396,980	Abstain
First Trust	0	351,058	Abstain
Bridge Builder Trust	334,408	0	For
T. Rowe Price	281,489	0	For
Equitable	230,743	0	For
AMG FUNDS	230,038	0	For
Jackson National	147,000	56,192	For
AIG/SunAmerica	0	179,784	Abstain
BUFFALO FUNDS	173,306	0	For
Principal Exchange-Traded Funds	0	163,367	Abstain
Lincoln Financial	74,800	68,824	For
Allspring	0	132,842	Abstain

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

5. To ratify the selection, by the Audit Committee of the Company's Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.

AUDIT-RELATED

100% fund support · no official result

FOR 99.9%

The 86 asset managers below cast 100% of the shares they voted on this item FOR (30,878,263 for, 0 against).

FOR: 30,878,263 (100.0%)ABSTAIN: 11,164 (0.0%)

Largest asset managers voting on “To ratify the selection, by the Audit Committee of the Company's Board of Directors, of Ernst & Young LLP, as ” at Arcutis Biotherapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	6,905,480	1	For
State Street	3,808,655	0	For
BlackRock	3,277,010	0	For
Fidelity	3,007,146	0	For
Prudential/PGIM	2,221,090	0	For
OBERWEIS FUNDS	1,211,800	0	For
American Century	1,120,551	0	For
Charles Schwab	1,012,955	0	For
TIAA	870,242	0	For
FRANKLIN STRATEGIC SERIES	850,058	0	For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)	710,000	0	For
Federated Hermes	689,843	0	For
Franklin Custodian Funds	400,000	0	For
DRIEHAUS MUTUAL FUNDS	396,980	0	For
First Trust	351,058	0	For
Bridge Builder Trust	334,408	0	For
T. Rowe Price	281,489	0	For
Equitable	230,743	0	For
AMG FUNDS	230,038	0	For
Jackson National	203,192	0	For
AIG/SunAmerica	179,784	0	For
BUFFALO FUNDS	173,306	0	For
Principal Exchange-Traded Funds	163,367	0	For
Lincoln Financial	143,624	0	For
Allspring	132,842	0	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

Largest Arcutis Biotherapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Arcutis Biotherapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 125,042,000 shares outstanding at the time of that meeting.

Top Arcutis Biotherapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	MONTANOVA CAPITAL, LLC	9.43%
2	Polar Capital Holdings Plc	8.57%
3	Frazier Life Sciences Management, L.P.	7.90%
4	Vanguard	6.26%
5	BlackRock	5.56%
6	State Street	4.88%
7	JENNISON ASSOCIATES LLC	3.43%
8	Rubric Capital Management LP	3.32%
9	Fidelity	2.63%
10	GEODE CAPITAL MANAGEMENT, LLC	2.44%

Reported Arcutis Biotherapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Arcutis Biotherapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Suvretta Capital Management, LLC	7.63%	DEF14A
BlackRock	7.36%	13F
Patrick J. Heron	7.08%	DEF14A
Frazier Life Sciences VIII, L.P.	7.03%	DEF14A
Rubric Capital Management LP	6.62%	13G
Vanguard Group	5.80%	13F
State Street	5.04%	13F
PRUDENTIAL FINANCIAL INC	4.24%	13G
Jennison Associates LLC	3.98%	13G
Morgan Stanley	3.47%	13F

Percentages above are of 125,042,000 shares outstanding, as reported by Arcutis Biotherapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Arcutis Biotherapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Arcutis Biotherapeutics, Inc.'s shareholder meeting held 2026-06-05, in the 2025-2026 proxy season, 307 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,547 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Arcutis Biotherapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-09.

Arcutis Biotherapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).